LAUSR

The conventional treatment is faced with limitations in the treatment of solid tumors due to the specific pathophysiology of them. In recent decades, several novel therapeutics have been introduced to treat solid tumors. Among these new methods, tumor therapy using bacterial products like bacteriocins and peptides has been of great interest due to the unique characteristics and advantages of them in comparison to the conventional treatment including that they are able to precisely target tumor cells, selective toxicity for tumor cells, low side effect on normal cells, toxicity activity for MDR cancer cells, used as the target delivery vehicles and enhancing drug delivery. Moreover, their small size and low molecular weight have made them easy to synthesize and modify. Furthermore, in recent years, use of genetic engineering has expanded the therapeutic ability of peptides to treat solid tumors, which results in overcoming the peptide drawbacks. The present review mainly focuses on the new advances in the application of bacterial peptides and bacteriocins in treating human solid tumors.